51 related articles for article (PubMed ID: 8306255)
1. Analysis of a conjugate between anti-carcinoembryonic antigen monoclonal antibody and alkaline phosphatase for specific activation of the prodrug etoposide phosphate.
Haisma HJ; Boven E; van Muijen M; De Vries R; Pinedo HM
Cancer Immunol Immunother; 1992; 34(5):343-8. PubMed ID: 1540981
[TBL] [Abstract][Full Text] [Related]
2. Isolation and molecular characterization of novel glucarpidases: Enzymes to improve the antibody directed enzyme pro-drug therapy for cancer treatment.
Rashidi FB; AlQhatani AD; Bashraheel SS; Shaabani S; Groves MR; Dömling A; Goda SK
PLoS One; 2018; 13(4):e0196254. PubMed ID: 29698433
[TBL] [Abstract][Full Text] [Related]
3. Poly(ethylene glycol) modification of beta-glucuronidase-antibody conjugates for solid-tumor therapy by targeted activation of glucuronide prodrugs.
Cheng TL; Chen BM; Chan LY; Wu PY; Chern JW; Roffler SR
Cancer Immunol Immunother; 1997 Aug; 44(6):305-15. PubMed ID: 9298932
[TBL] [Abstract][Full Text] [Related]
4. Engineering carboxypeptidase G2 circular permutations for the design of an autoinhibited enzyme.
Yachnin BJ; Khare SD
Protein Eng Des Sel; 2017 Apr; 30(4):321-331. PubMed ID: 28160000
[TBL] [Abstract][Full Text] [Related]
5. Development of a
Lee JP; Corless BC; Gardner TJ; Scheinberg DA; Tan DS
Org Lett; 2023 Sep; 25(34):6295-6299. PubMed ID: 37602700
[TBL] [Abstract][Full Text] [Related]
6. LEAPT: lectin-directed enzyme-activated prodrug therapy.
Robinson MA; Charlton ST; Garnier P; Wang XT; Davis SS; Perkins AC; Frier M; Duncan R; Savage TJ; Wyatt DA; Watson SA; Davis BG
Proc Natl Acad Sci U S A; 2004 Oct; 101(40):14527-32. PubMed ID: 15448212
[TBL] [Abstract][Full Text] [Related]
7. Tumor labeling in vivo using cyanine-conjugated monoclonal antibodies.
Ballou B; Fisher GW; Waggoner AS; Farkas DL; Reiland JM; Jaffe R; Mujumdar RB; Mujumdar SR; Hakala TR
Cancer Immunol Immunother; 1995 Oct; 41(4):257-63. PubMed ID: 7489569
[TBL] [Abstract][Full Text] [Related]
8. Complementation Dependent Enzyme Prodrug Therapy Enables Targeted Activation of Prodrug on HER2-Positive Cancer Cells.
Nervig CS; Hatch ST; Owen SC
ACS Med Chem Lett; 2022 Nov; 13(11):1769-1775. PubMed ID: 36385932
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and preliminary cytotoxicity study of a cephalosporin-CC-1065 analogue prodrug.
Wang Y; Yuan H; Wright SC; Wang H; Larrick JW
BMC Chem Biol; 2001; 1(1):4. PubMed ID: 11710971
[TBL] [Abstract][Full Text] [Related]
10. Bringing enzymes to the proximity party.
Tender GS; Bertozzi CR
RSC Chem Biol; 2023 Nov; 4(12):986-1002. PubMed ID: 38033727
[TBL] [Abstract][Full Text] [Related]
11. Glycoengineering of pertuzumab and its impact on the pharmacokinetic/pharmacodynamic properties.
Luo C; Chen S; Xu N; Wang C; Sai WB; Zhao W; Li YC; Hu XJ; Tian H; Gao XD; Yao WB
Sci Rep; 2017 Apr; 7():46347. PubMed ID: 28397880
[TBL] [Abstract][Full Text] [Related]
12. Novel integrin-targeted binding-triggered drug delivery system for methotrexate.
Kotamraj P; Russu WA; Jasti B; Wu J; Li X
Pharm Res; 2011 Dec; 28(12):3208-19. PubMed ID: 21695561
[TBL] [Abstract][Full Text] [Related]
13. A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours.
Francis RJ; Sharma SK; Springer C; Green AJ; Hope-Stone LD; Sena L; Martin J; Adamson KL; Robbins A; Gumbrell L; O'Malley D; Tsiompanou E; Shahbakhti H; Webley S; Hochhauser D; Hilson AJ; Blakey D; Begent RH
Br J Cancer; 2002 Sep; 87(6):600-7. PubMed ID: 12237768
[TBL] [Abstract][Full Text] [Related]
14. Altered biodistribution of an antibody--enzyme conjugate modified with polyethylene glycol.
Eno-Amooquaye EA; Searle F; Boden JA; Sharma SK; Burke PJ
Br J Cancer; 1996 Jun; 73(11):1323-7. PubMed ID: 8645574
[TBL] [Abstract][Full Text] [Related]
15. Problems of delivery of monoclonal antibodies. Pharmaceutical and pharmacokinetic solutions.
Reilly RM; Sandhu J; Alvarez-Diez TM; Gallinger S; Kirsh J; Stern H
Clin Pharmacokinet; 1995 Feb; 28(2):126-42. PubMed ID: 7736688
[TBL] [Abstract][Full Text] [Related]
16. Galactosylated antibodies and antibody-enzyme conjugates in antibody-directed enzyme prodrug therapy.
Sharma SK; Bagshawe KD; Burke PJ; Boden JA; Rogers GT; Springer CJ; Melton RG; Sherwood RF
Cancer; 1994 Feb; 73(3 Suppl):1114-20. PubMed ID: 8306255
[TBL] [Abstract][Full Text] [Related]
17. Plasma clearance of an antibody--enzyme conjugate in ADEPT by monoclonal anti-enzyme: its effect on prodrug activation in vivo.
Rogers GT; Burke PJ; Sharma SK; Koodie R; Boden JA
Br J Cancer; 1995 Dec; 72(6):1357-63. PubMed ID: 8519645
[TBL] [Abstract][Full Text] [Related]
18. Antibody-directed enzyme prodrug therapy (ADEPT). A three-phase study in ovarian tumor xenografts.
Sharma SK; Boden JA; Springer CJ; Burke PJ; Bagshawe KD
Cell Biophys; 1994; 24-25():219-28. PubMed ID: 7736526
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
